Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 256

1.

Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program.

Maines F, De Giorgi U, Procopio G, Facchini G, Fratino L, Sabbatini R, Gasparro D, Basso U, Mosillo C, Campadelli E, Massari F, Sava T, Sirotova S, Messina C, Scagliarini S, Conteduca V, Verzoni E, Rossetti S, Veccia A, Kinspergher S, Caffo O.

Future Oncol. 2018 Sep 12. doi: 10.2217/fon-2018-0113. [Epub ahead of print]

PMID:
30207488
2.

Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program.

Prisciandaro M, Ratta R, Massari F, Fornarini G, Caponnetto S, Iacovelli R, De Giorgi U, Facchini G, Scagliarini S, Sabbatini R, Caserta C, Peverelli G, Mennitto A, Verzoni E, Procopio G.

Am J Clin Oncol. 2018 Sep 10. doi: 10.1097/COC.0000000000000478. [Epub ahead of print]

PMID:
30204614
3.

The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.

Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C.

Anticancer Drugs. 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632.

PMID:
29846246
4.

Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?

Iacovelli R, De Giorgi U, Galli L, Zucali P, Nolè F, Sabbatini R, Fraccon AP, Basso U, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Pasini F, Masini C, Massari F, Buti S, Sava T, Sacco C, Ricotta R, Sperduti I, Tortora G, Porta C.

Clin Genitourin Cancer. 2018 May 7. pii: S1558-7673(18)30151-4. doi: 10.1016/j.clgc.2018.04.007. [Epub ahead of print]

PMID:
29803346
5.

Coffee consumption is not associated with ovarian cancer risk: a dose-response meta-analysis of prospective cohort studies.

Berretta M, Micek A, Lafranconi A, Rossetti S, Di Francia R, De Paoli P, Rossi P, Facchini G.

Oncotarget. 2018 Apr 17;9(29):20807-20815. doi: 10.18632/oncotarget.24829. eCollection 2018 Apr 17.

6.

Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.

Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Cartenì G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, Vernieri C, Santini D, Sorarù M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, Verzoni E.

Clin Genitourin Cancer. 2018 Aug;16(4):e945-e951. doi: 10.1016/j.clgc.2018.03.014. Epub 2018 Apr 19.

PMID:
29753637
7.

Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.

Gordon JA, Buonerba C, Pond G, Crona D, Gillessen S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke JA, Bosso D, Milowsky MI, Witek MS, Battaglia M, Pignata S, Cherhroudi C, Cox ME, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl BJ, Di Lorenzo G.

Oncotarget. 2018 Apr 13;9(28):19861-19873. doi: 10.18632/oncotarget.24888. eCollection 2018 Apr 13.

8.

Microbiota effects on cancer: from risks to therapies.

Rea D, Coppola G, Palma G, Barbieri A, Luciano A, Del Prete P, Rossetti S, Berretta M, Facchini G, Perdonà S, Turco MC, Arra C.

Oncotarget. 2018 Apr 3;9(25):17915-17927. doi: 10.18632/oncotarget.24681. eCollection 2018 Apr 3. Review.

9.

Processed Meat and Risk of Renal Cell and Bladder Cancers.

Rosato V, Negri E, Serraino D, Montella M, Libra M, Lagiou P, Facchini G, Ferraroni M, Decarli A, La Vecchia C.

Nutr Cancer. 2018 Apr;70(3):418-424. doi: 10.1080/01635581.2018.1445764. Epub 2018 Mar 23.

PMID:
29570985
10.

Change in FGF-2 circulating levels after arterial embolization in patients with bone metastases.

Rossi G, Salerno M, Granchi D, Cenni E, Facchini G, Baldini N.

Neoplasma. 2018;65(2):262-268. doi: 10.4149/neo_2018_170204N74.

PMID:
29534588
11.

Diffuse lung disease associated with neurofibromatosis type-1 can also affect children.

Spinnato P, Facchini G, Bazzocchi A, Albisinni U.

World J Pediatr. 2018 Apr;14(2):207. doi: 10.1007/s12519-018-0149-3. Epub 2018 Mar 7. No abstract available.

PMID:
29516392
12.

Successful selective arterial embolizations for bone metastases in renal cell carcinoma integrated with systemic therapies: A case report.

Gatto L, Facchini G, Saponara M, Nannini M, Rossi G, Di Scioscio V, Biasco G, Pantaleo MA.

Radiol Case Rep. 2017 Aug 16;12(4):775-779. doi: 10.1016/j.radcr.2017.07.008. eCollection 2017 Dec.

13.

Biopsy is not necessary for the diagnosis of soft tissue hemangiomas.

Rimondi E, Mavrogenis AF, Errani C, Calabrò T, Bazzocchi A, Facchini G, Donatiello S, Spinnato P, Vanel D, Albisinni U, Pelotti P.

Radiol Med. 2018 Jul;123(7):538-544. doi: 10.1007/s11547-018-0862-y. Epub 2018 Feb 23.

PMID:
29476440
14.

Health-related quality of life and psychosocial implications in testicular cancer survivors. A literature review.

Cappuccio F, Rossetti S, Cavaliere C, Iovane G, Taibi R, D'Aniello C, Imbimbo C, Facchini S, Abate V, Barberio D, Facchini G.

Eur Rev Med Pharmacol Sci. 2018 Feb;22(3):645-661. doi: 10.26355/eurrev_201802_14290.

15.

Exploring the molecular aspects associated with testicular germ cell tumors: a review.

Facchini G, Rossetti S, Cavaliere C, D'Aniello C, Di Franco R, Iovane G, Grimaldi G, Piscitelli R, Muto P, Botti G, Perdonà S, Veneziani BM, Berretta M, Montanari M.

Oncotarget. 2017 Nov 3;9(1):1365-1379. doi: 10.18632/oncotarget.22373. eCollection 2018 Jan 2. Review.

16.

Proanthocyanidins and the risk of prostate cancer in Italy.

Praud D, Parpinel M, Guercio V, Bosetti C, Serraino D, Facchini G, Montella M, La Vecchia C, Rossi M.

Cancer Causes Control. 2018 Feb;29(2):261-268. doi: 10.1007/s10552-018-1002-7. Epub 2018 Jan 19.

PMID:
29350310
17.

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.

Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K.

Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8.

PMID:
29326030
18.

Ipilimumab for the treatment of metastatic prostate cancer.

Alaia C, Boccellino M, Zappavigna S, Amler E, Quagliuolo L, Rossetti S, Facchini G, Caraglia M.

Expert Opin Biol Ther. 2018 Feb;18(2):205-213. doi: 10.1080/14712598.2018.1420777. Epub 2017 Dec 28.

PMID:
29271259
19.

Testicular cancer from diagnosis to epigenetic factors.

Boccellino M, Vanacore D, Zappavigna S, Cavaliere C, Rossetti S, D'Aniello C, Chieffi P, Amler E, Buonerba C, Di Lorenzo G, Di Franco R, Izzo A, Piscitelli R, Iovane G, Muto P, Botti G, Perdonà S, Caraglia M, Facchini G.

Oncotarget. 2017 Sep 18;8(61):104654-104663. doi: 10.18632/oncotarget.20992. eCollection 2017 Nov 28. Review.

20.

Epigenetic Changes Induced by Green Tea Catechins a re Associated with Prostate Cancer.

Giudice A, Montella M, Boccellino M, Crispo A, D'Arena G, Bimonte S, Facchini G, Ciliberto G, Botti G, Quagliuolo L, Caraglia M, Capunzo M.

Curr Mol Med. 2017;17(6):405-420. doi: 10.2174/1566524018666171219101937.

PMID:
29256350
21.

The utility of contrast-enhanced hypodense sign for the diagnosis of pulmonary invasive mould disease in patients with haematological malignancies.

Sassi C, Stanzani M, Lewis RE, Facchini G, Bazzocchi A, Cavo M, Battista G.

Br J Radiol. 2018 Feb;91(1083):20170220. doi: 10.1259/bjr.20170220. Epub 2018 Jan 10.

PMID:
29212355
22.

Radiosurgery and stereotactic radiotherapy with cyberknife system for meningioma treatment.

Di Franco R, Borzillo V, Ravo V, Falivene S, Romano FJ, Muto M, Cammarota F, Totaro G, Ametrano G, Rossetti S, Cavaliere C, D' Aniello C, Iovane G, Porricelli MA, Berretta M, Botti G, Starace L, Salvia E, Facchini G, Muto P.

Neuroradiol J. 2018 Feb;31(1):18-26. doi: 10.1177/1971400917744885. Epub 2017 Dec 5.

PMID:
29206077
23.

Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results.

Di Francia R, Atripaldi L, Di Martino S, Fierro C, Muto T, Crispo A, Rossetti S, Facchini G, Berretta M.

Front Pharmacol. 2017 Nov 7;8:797. doi: 10.3389/fphar.2017.00797. eCollection 2017.

24.

Toxic effects of phytol and retinol on human glioblastoma cells are associated with modulation of cholesterol and fatty acid biosynthetic pathways.

Facchini G, Ignarro RS, Rodrigues-Silva E, Vieira AS, Lopes-Cendes I, Castilho RF, Rogerio F.

J Neurooncol. 2018 Feb;136(3):435-443. doi: 10.1007/s11060-017-2672-9. Epub 2017 Nov 20.

PMID:
29159775
25.

Coffee Decreases the Risk of Endometrial Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies.

Lafranconi A, Micek A, Galvano F, Rossetti S, Del Pup L, Berretta M, Facchini G.

Nutrients. 2017 Nov 9;9(11). pii: E1223. doi: 10.3390/nu9111223. Review.

26.

Associations of dietary carbohydrates, glycaemic index and glycaemic load with risk of bladder cancer: a case-control study.

Augustin LSA, Taborelli M, Montella M, Libra M, La Vecchia C, Tavani A, Crispo A, Grimaldi M, Facchini G, Jenkins DJA, Botti G, Serraino D, Polesel J.

Br J Nutr. 2017 Nov;118(9):722-729. doi: 10.1017/S0007114517002574. Epub 2017 Oct 9.

PMID:
28990544
27.

Correction: Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.

Quagliariello V, Rossetti S, Cavaliere C, Di Palo R, Lamantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Romano FJ, Piscitelli R, Iovane G, Pepe MF, Berretta M, D'Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, Caraglia M, Montella M, Iaffaioli RV, Facchini G.

Oncotarget. 2017 Sep 22;8(37):62816. doi: 10.18632/oncotarget.20631. eCollection 2017 Sep 22.

28.

Rectal/urinary toxicity after hypofractionated vs. conventional radiotherapy in high risk prostate cancer: systematic review and meta analysis.

Di Franco R, Borzillo V, Ravo V, Ametrano G, Cammarota F, Rossetti S, Romano FJ, D'Aniello C, Cavaliere C, Iovane G, Porricelli MA, Muto M, Berretta M, Facchini G, Muto P.

Eur Rev Med Pharmacol Sci. 2017 Aug;21(16):3563-3575. Review.

29.

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma.

Rossetti S, D'Aniello C, Iovane G, Scagliarini S, Laterza MM, De Vita F, Savastano C, Cartenì G, Porricelli MA, Berretta M, Pisconti S, Facchini G, Cavaliere C.

Front Pharmacol. 2017 Jul 20;8:484. doi: 10.3389/fphar.2017.00484. eCollection 2017.

30.

Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate.

Di Lorenzo G, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Cartenì G, Federico P, Daniele B, Morelli F, Bellelli T, Ferro M, De Placido S, Buonerba C.

Eur Urol Focus. 2017 Apr 8. pii: S2405-4569(17)30083-4. doi: 10.1016/j.euf.2017.03.015. [Epub ahead of print]

PMID:
28753882
31.

A rare case of malignant solitary fibrous tumor in prostate with review of the literature.

Ronchi A, La Mantia E, Gigantino V, Perdonà S, De Sio M, Facchini G, Franco R, De Chiara A.

Diagn Pathol. 2017 Jul 7;12(1):50. doi: 10.1186/s13000-017-0640-5. Review.

32.

ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review.

Botti G, Malzone MG, La Mantia E, Montanari M, Vanacore D, Rossetti S, Quagliariello V, Cavaliere C, Di Franco R, Castaldo L, Ametrano G, Cappuccio F, Romano FJ, Piscitelli R, Pepe MF, D'Aniello C, Facchini G.

Int J Med Sci. 2017 Apr 21;14(6):554-559. doi: 10.7150/ijms.17890. eCollection 2017. Review.

33.

PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study.

Bosso D, Pagliuca M, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Cartenì G, Daniele B, Morelli F, Ferro M, Puglia L, Izzo M, Montanaro V, Bellelli T, Vitrone F, De Placido S, Buonerba C, Di Lorenzo G.

Medicine (Baltimore). 2017 Jun;96(24):e6817. doi: 10.1097/MD.0000000000006817.

34.

Ultraviolet A photosensitivity profile of dexchlorpheniramine maleate and promethazine-based creams: Anti-inflammatory, antihistaminic, and skin barrier protection properties.

Facchini G, Eberlin S, Clerici SP, Alves Pinheiro ALT, Costa A.

J Cosmet Dermatol. 2017 Dec;16(4):e59-e67. doi: 10.1111/jocd.12349. Epub 2017 Jun 7.

PMID:
28593645
35.

Spinal osteoid osteoma: efficacy and safety of radiofrequency ablation.

Albisinni U, Facchini G, Spinnato P, Gasbarrini A, Bazzocchi A.

Skeletal Radiol. 2017 Aug;46(8):1087-1094. doi: 10.1007/s00256-017-2662-1. Epub 2017 May 11.

PMID:
28497160
36.

Micrornas in prostate cancer: an overview.

Vanacore D, Boccellino M, Rossetti S, Cavaliere C, D'Aniello C, Di Franco R, Romano FJ, Montanari M, La Mantia E, Piscitelli R, Nocerino F, Cappuccio F, Grimaldi G, Izzo A, Castaldo L, Pepe MF, Malzone MG, Iovane G, Ametrano G, Stiuso P, Quagliuolo L, Barberio D, Perdonà S, Muto P, Montella M, Maiolino P, Veneziani BM, Botti G, Caraglia M, Facchini G.

Oncotarget. 2017 Jul 25;8(30):50240-50251. doi: 10.18632/oncotarget.16933. Review.

37.

Epithelial-mesenchymal transition in prostate cancer: an overview.

Montanari M, Rossetti S, Cavaliere C, D'Aniello C, Malzone MG, Vanacore D, Di Franco R, La Mantia E, Iovane G, Piscitelli R, Muscariello R, Berretta M, Perdonà S, Muto P, Botti G, Bianchi AAM, Veneziani BM, Facchini G.

Oncotarget. 2017 May 23;8(21):35376-35389. doi: 10.18632/oncotarget.15686. Review.

38.

Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.

Conteduca V, Caffo O, Lolli C, Aieta M, Scarpi E, Bianchi E, Maines F, Schepisi G, Salvi S, Massari F, Carrozza F, Veccia A, Chiuri VE, Campadelli E, Facchini G, De Giorgi U.

Prostate. 2017 Jun;77(9):1012-1019. doi: 10.1002/pros.23357. Epub 2017 Apr 20.

PMID:
28429372
39.

Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.

Quagliariello V, Rossetti S, Cavaliere C, Di Palo R, Lamantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Romano FJ, Piscitelli R, Iovane G, Pepe MF, Berretta M, D'Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, Caraglia M, Montella M, Iaffaioli RV, Facchini G.

Oncotarget. 2017 May 2;8(18):30606-30616. doi: 10.18632/oncotarget.16725. Review. Erratum in: Oncotarget. 2017 Sep 22;8(37):62816.

40.

Family history of cancer and the risk of bladder cancer: A case-control study from Italy.

Turati F, Bosetti C, Polesel J, Serraino D, Montella M, Libra M, Facchini G, Ferraroni M, Tavani A, La Vecchia C, Negri E.

Cancer Epidemiol. 2017 Jun;48:29-35. doi: 10.1016/j.canep.2017.03.003. Epub 2017 Mar 28.

PMID:
28363161
41.

Serum and tissue markers in colorectal cancer: State of art.

Berretta M, Alessandrini L, De Divitiis C, Nasti G, Lleshi A, Di Francia R, Facchini G, Cavaliere C, Buonerba C, Canzonieri V.

Crit Rev Oncol Hematol. 2017 Mar;111:103-116. doi: 10.1016/j.critrevonc.2017.01.007. Epub 2017 Jan 27. Review.

PMID:
28259285
42.

Honokiol protects skin cells against inflammation, collagenolysis, apoptosis, and senescence caused by cigarette smoke damage.

Costa A, Facchini G, Pinheiro ALTA, da Silva MS, Bonner MY, Arbiser J, Eberlin S.

Int J Dermatol. 2017 Jul;56(7):754-761. doi: 10.1111/ijd.13569. Epub 2017 Feb 22.

43.

Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey.

Berretta M, Della Pepa C, Tralongo P, Fulvi A, Martellotta F, Lleshi A, Nasti G, Fisichella R, Romano C, De Divitiis C, Taibi R, Fiorica F, Di Francia R, Di Mari A, Del Pup L, Crispo A, De Paoli P, Santorelli A, Quagliariello V, Iaffaioli RV, Tirelli U, Facchini G.

Oncotarget. 2017 Apr 11;8(15):24401-24414. doi: 10.18632/oncotarget.14224.

44.

A comprehensive review of pulsed radiofrequency in the treatment of pain associated with different spinal conditions.

Facchini G, Spinnato P, Guglielmi G, Albisinni U, Bazzocchi A.

Br J Radiol. 2017 May;90(1073):20150406. doi: 10.1259/bjr.20150406. Epub 2017 Feb 10. Review.

45.

Current and Emerging Treatments for Metastatic Renal Cell Carcinoma.

Cavaliere C, D'Aniello C, Pepa CD, Pisconti S, Berretta M, Facchini G.

Curr Cancer Drug Targets. 2018;18(5):468-479. doi: 10.2174/1568009617666170209094030.

PMID:
28183256
46.

Melanoma Adjuvant Treatment: Current Insight and Clinical Features.

D'Aniello C, Perri F, Scarpati GDV, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M, Cavaliere C.

Curr Cancer Drug Targets. 2018;18(5):442-456. doi: 10.2174/1568009617666170208163714.

PMID:
28183255
47.

Optimal Management of Prostate Cancer Based on its Natural Clinical History.

Facchini G, Perri F, Misso G, D'Aniello C, Scarpati GDV, Rossetti S, Pepa CD, Pisconti S, Unteregger G, Cossu A, Caraglia M, Berretta M, Cavaliere C.

Curr Cancer Drug Targets. 2018;18(5):457-467. doi: 10.2174/1568009617666170209093101.

PMID:
28183253
48.

The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration.

Berretta M, Romano C, Di Francia R, De Diviitis C, Canzonieri V, Caraglia M, Facchini G, Nasti G.

Curr Cancer Drug Targets. 2018;18(5):430-441. doi: 10.2174/1568009617666170208162058.

PMID:
28183250
49.

Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.

Di Franco R, Borzillo V, Ravo V, Ametrano G, Falivene S, Cammarota F, Rossetti S, Romano FJ, D'Aniello C, Cavaliere C, Iovane G, Piscitelli R, Berretta M, Muto P, Facchini G.

Oncotarget. 2017 Mar 7;8(10):17383-17395. doi: 10.18632/oncotarget.14798. Review.

50.

First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.

Buti S, Bersanelli M, Maines F, Facchini G, Gelsomino F, Zustovich F, Santoni M, Verri E, De Giorgi U, Masini C, Morelli F, Vitale MG, Sava T, Prati G, Librici C, Fraccon AP, Fornarini G, Maruzzo M, Leonardi F, Caffo O.

Clin Genitourin Cancer. 2017 Aug;15(4):e609-e614. doi: 10.1016/j.clgc.2016.12.024. Epub 2016 Dec 29.

PMID:
28108284

Supplemental Content

Loading ...
Support Center